BlackRock Health Sciences Term Trust (BMEZ) To Go Ex-Dividend on November 15th

BlackRock Health Sciences Term Trust (NYSE:BMEZ) declared a monthly dividend on Friday, November 1st,NASDAQ Dividends reports. Stockholders of record on Friday, November 15th will be paid a dividend of 0.1769 per share on Friday, November 29th. This represents a $2.12 annualized dividend and a dividend yield of 13.53%. The ex-dividend date of this dividend is Friday, November 15th.

BlackRock Health Sciences Term Trust has increased its dividend by an average of 20.7% per year over the last three years.

BlackRock Health Sciences Term Trust Stock Down 0.9 %

Shares of BlackRock Health Sciences Term Trust stock traded down 0.15 on Wednesday, hitting 15.69. The stock had a trading volume of 215,358 shares, compared to its average volume of 264,385. BlackRock Health Sciences Term Trust has a one year low of 13.41 and a one year high of 16.59. The stock’s 50-day simple moving average is 15.80 and its two-hundred day simple moving average is 15.56.

Insider Buying and Selling

In other news, major shareholder Saba Capital Management, L.P. acquired 15,455 shares of the stock in a transaction on Thursday, September 19th. The stock was acquired at an average price of 16.14 per share, with a total value of 249,443.70. Following the completion of the transaction, the insider now owns 20,601,568 shares of the company’s stock, valued at 332,509,307.52. This represents a 0.00 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders acquired 99,630 shares of company stock valued at $1,585,113 over the last quarter.

About BlackRock Health Sciences Term Trust

BlackRock Health Sciences Trust II’s (BMEZ) (the ‘Trust’) investment objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities of companies principally engaged in the health sciences group of industries and equity derivatives with exposure to the health sciences group of industries.